Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
2.560
+0.005 (0.20%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Kiora Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2024
-
Two small molecule assets target major unmet needs in retinal diseases, with KIO-104 advancing to phase II for inflammation and KIO-301 leveraging a photoswitch approach for inherited blindness. Strategic partnership with Théa secures funding and commercialization in the U.S. and Europe, while global rights for KIO-104 are retained.
-
The presentation highlighted progress on two key assets for retinal diseases, with KIO-301 advancing into phase II trials and supported by a major partnership, and KIO-104 preparing for phase II in 2025. Strong financials and regulatory alignment position the company for multiple value inflection points.